Phase IIa – Neuropathic Pain
LAT-NP-001 a Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain is currently underway, using twice daily delivery of 30mg of LAT8881 by capsule for the treatment of the painful symptoms of post herpetic neuralgia and diabetic neuropathy. Lateral Pharma is looking for efficacy at least comparable to Lyrica and clinical safety comparable to prior clinical studies with LAT8881.
LAT-NP-001 started in March 2019 at four Australian sites: Melbourne, Western Sydney, Central Coast and Brisbane. Two UK sites commenced in October, Bristol and Glasgow.
The clinical trial protocol for this study was developed by Lateral’s in-house team, with input from the clinical advisory board and experienced clinicians including Prof Paul Rolan, Prof Ralf Baron, Prof Tony Pickering and Prof Andy Rice.
Phase IIa – Migraine
LAT-MIG-001 a Phase lla Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine is currently underway, using two 30mg capsules of LAT8881 with the onset of migraine.
LAT-MIG-001 started in October 2019 at three Australian sites: Melbourne, Western Sydney and NSW Central Coast.